Skip to main content
. 2023 Jun 10;13(8):1733–1746. doi: 10.1007/s13555-023-00937-9

Table 2.

Baseline comorbidities and history of surgical procedures in the AA and matched non-AA cohorts

History of comorbid conditions, n (%) AA cohort (n = 8784) Non-AA cohort (n = 26,352) AT/AU subtype (n = 599) Non-AT/AU subtype (n = 8185)
Hypertension 2233 (25.4) 6409 (24.3) 234 (39.1) 1999 (24.4)
Diabetes mellitus 802 (9.1) 2791 (10.6) 81 (13.5) 721 (8.8)
Hyperlipidemia 2364 (26.9) 6301 (23.9) 235 (39.2) 2129 (26.0)
Smoking
 Current 754 (8.6) 2269 (8.6) 62 (10.4) 692 (8.5)
 Previous 38 (0.4) 157 (0.6) 4 (0.7) 34 (0.4)
 Never 416 (4.7) 932 (3.5) 26 (4.3) 390 (4.8)
 Unknown 27 (0.3) 48 (0.2) 1 (0.2) 26 (0.3)
Substance abuse 228 (2.6) 601 (2.3) 18 (3.0) 210 (2.6)
Obesity
 Yes 999 (11.4) 2556 (9.7) 103 (17.2) 896 (10.9)
COPD 275 (3.1) 832 (3.2) 51 (8.5) 224 (2.7)
Any primary malignancya 373 (4.2) 919 (3.5) 50 (8.3) 323 (3.9)
BCC 87 (1.0) 238 (0.9) 8 (1.3) 79 (1.0)
SCC 52 (0.6) 119 (0.5) 10 (1.7) 42 (0.5)
Cervical carcinoma in situ 6 (0.1) 20 (0.1) 0 6 (0.1)
Malignant melanoma 16 (0.2) 47 (0.2) 1 (0.2) 15 (0.2)
Lymphoma 29 (0.3) 50 (0.2) 3 (0.5) 26 (0.3)
Female breast cancer 78 (0.9) 191 (0.7) 14 (2.3) 64 (0.8)
Acute myocardial infarction 42 (0.5) 108 (0.4) 8 (1.3) 34 (0.4)
Unstable angina 15 (0.2) 61 (0.2) 2 (0.3) 13 (0.2)
Ischemic stroke 17 (0.2) 42 (0.2) 1 (0.2) 16 (0.2)
Hemorrhagic stroke 2 (< 0.1) 6 (< 0.1) 1 (0.2) 1 (0)
Hospitalization due to heart failure 64 (0.7) 172 (0.7) 9 (1.5) 55 (0.7)
Coronary revascularization by PCI or CABG 22 (0.3) 76 (0.3) 2 (0.3) 20 (0.2)
DVT 60 (0.7) 133 (0.5) 10 (1.7) 50 (0.6)
PE 28 (0.3) 83 (0.3) 4 (0.7) 24 (0.3)
DVT or PE 76 (0.9) 188 (0.7) 12 (2.0) 64 (0.8)
ATE 7 (0.1) 27 (0.1) 0 7 (0.1)
DVT or PE or ATE 81 (0.9) 208 (0.8) 12 (2.0) 69 (0.8)
History of any surgery in the last 6 months prior to index date 117 (1.3) 353 (1.3) 17 (2.8) 100 (1.2)

AA alopecia areata, AT alopecia totalis, ATE arterial thromboembolism, AU alopecia universalis, BCC basal cell carcinoma, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, DVT deep vein thrombosis, PCI percutaneous coronary intervention, PE pulmonary embolism, SCC squamous cell carcinoma

aExcluding nonmelanoma skin cancer